This site is intended for healthcare professionals only
This site is intended for healthcare professionals only
Hamilton Fairley Professor of Medical Oncology, Centre Lead, Centre for Haemato-Oncology, Barts Cancer Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London
Professor John Gribben, MD, DSc, FMedSci, leads the Centre for Haemato-Oncology at Barts Cancer Institute at Queen Mary, University of London, UK, where he holds the Gordon Hamilton Fairley Chair of Medical Oncology. He is an honorary consultant in haemato-oncology, established the ECMC at Barts and is director of the Stem Cell Transplantation Program at St Bartholomew’s Hospital. He completed his doctoral studies at University College London and continued his postdoctoral training in medical oncology and then joined the Faculty at the Dana-Farber Cancer, Harvard Medical School, Boston Massachusetts, USA from 1989 to 2015.
He is an author of more than 500 peer-reviewed articles and book chapters. He was awarded the Binet-Rai medal from the international workshop for CLL (iwCLL) for his pioneering CLL research in 2017. He served as an Editor of Blood from 2007 to 2014. He is a Fellow of the Royal College of Physicians, and the Royal College of Pathologists. He was elected as a member of the American Society for Clinical Investigation and a Fellow of the Academy of Medical Science. He is Chair of the international workshop on non-Hodgkin’s Lymphoma (iwNHL) and Co-Chair of the international workshop for CAR-T cells (iwCART). He serves on the Executive Board and is currently President of the European Hematology Association.
Hospital da Luz, Lisbon, Portugal
Professor Antonio Almeida is currently head of department at Hospital da Luz, Lisbon, Portugal, and also head of the hemato-oncology diagnostic laboratory at the Portuguese Institute of Oncology in Lisbon.
He was awarded his medical degree in 1993 from Cambridge University, UK, and completed his Specialist Training in Hematology in the UK in 2002. Following this, Professor Almeida completed a clinical research fellowship through the Leukaemia Research Fund at Imperial College, London, and was awarded a PhD in 2007 for his work on the molecular characterization and targeted therapy for Inherited GPI Deficiency.
Professor Almeida’s research interests include myeloproliferative and myelodysplastic syndromes, focusing on epigenetic regulation of transcription regulation. He leads a Hematology Epigenetic research group and is the national principal investigator for several clinical trials in CML and MDS.
Professor Almeida has been involved in pre-clinical and clinical teaching since his time as an intern. He is currently Associate Professor at NOVA medical school in Lisbon and has been appointed Founding Dean for the Católica University Medical School. He is heavily involved in post-graduate education: as Chair of the European Hematology Association Curriculum Committee, member of the Education Committee and EHA Secretary in the Association’s Executive Board.
Professor Almeida has written book chapters and is the author of more than 60 articles published in journals including New England Journal of Medicine, Nature Medicine and Blood.
University of Helsinki; Department of Hematology at the Helsinki University Hospital Comprehensive Cancer Center in Finland
Kimmo Porkka, MD, PhD, is a professor of clinical hematology at the University of Helsinki and his current clinical position is Head of the Department of Hematology at the Helsinki University Hospital Comprehensive Cancer Center in Finland.
Professor Porkka received his medical degrees at the Universities of Turku and Helsinki in Finland. He has received clinical training in oncology, internal medicine and hematology.
Professor Porkka`s research experience includes clinical epidemiology, clinical breast cancer research, human molecular genetics (genetic mapping of complex diseases), basic and applied cancer research on characterization of leukemia-specific proteins and ligands (post-doctoral visit at the Burnham Institute, La Jolla, USA).
Professor Porkka`s research relate to molecularly targeted therapies and immunotherapy of hematological malignancies. He has been the principal investigator in several Phase I-III clinical drug studies (academic and company-sponsored) on chronic myeloid leukemia and acute lymphoblastic and myeloid leukemia and performed closely linked translational science projects on leukemic stem cell targeting and immunomodulatory effects of tyrosine kinase inhibitors. Current research of Professor Porkka focuses on individualized therapy of relapsed acute leukemia by high-throughput predictive drug testing ex vivo and molecular profiling aiming in rapid introduction of novel therapies (e.g. by drug repurposing). He is particularly interested in applying mathematical modeling for integration of big disease profiling data sources for clinical translation.
Professor Porkka is the principal investigator in the Finnish Hematology Registry and Biobank (FHRB; fhrb.fi), which is a national, population-based registry and biobanking effort commencing in 2011. He is the past chairman of the Finnish Hematology Association.
Professor Porkka is an active member of the European Hematology Association (EHA), currently serving in the EHA Executive Board and as the chair of the scientific program committee for the EHA annual meeting in 2020.
Professor Porkka has more than 140 original publications in international peer reviewed journals, such as New England Journal of Medicine, Nature, Nature Medicine, Nature Genetics, PNAS, Journal of Clinical Oncology, Blood, and Leukemia.
Institute of Pharmacology and Toxicology, Department of Biomedical Sciences, University of Veterinary Medicine of Vienna, Austria
Professor Veronika Sexl is Chair in the Department of Biomedical Sciences, Veterinary Medical University Vienna, Austria. She completed her doctoral studies at University of Vienna.
Professor Sexl’s research interests include understanding signaling pathways involved in hematopoiesis, leukemogenesis and NK biology, particularly the role of JAK-STAT signaling in cancer and NK cells. Her recent work investigated the role of the cell cycle kinase CDK6 as a transcriptional regulator. Professor Sexl’s laboratory performs translational research using a broad range of techniques such as murine and human cell models, leukemia models, and primary clinical patient material.
Professor Sexl is Incoming Director for the Training Program in Translational Medicine of the American Society for Hematology (ASH) and the European Hematology Association (EHA). Since 2019, Professor Sexl has been Vice-Chair of the International Scientific Committee of the CRIS Cancer Foundation. Professor Sexl is a referee for international journals such as Nature and Blood.
Hamilton Fairley Professor of Medical Oncology, Centre Lead, Centre for Haemato-Oncology, Barts Cancer Institute, Barts and The London School of Medicine and Dentistry, Queen Mary University of London
Professor John Gribben, MD, DSc, FMedSci, leads the Centre for Haemato-Oncology at Barts Cancer Institute at Queen Mary, University of London, UK, where he holds the Gordon Hamilton Fairley Chair of Medical Oncology. He is an honorary consultant in haemato-oncology, established the ECMC at Barts and is director of the Stem Cell Transplantation Program at St Bartholomew’s Hospital. He completed his doctoral studies at University College London and continued his postdoctoral training in medical oncology and then joined the Faculty at the Dana-Farber Cancer, Harvard Medical School, Boston Massachusetts, USA from 1989 to 2015.
He is an author of more than 500 peer-reviewed articles and book chapters. He was awarded the Binet-Rai medal from the international workshop for CLL (iwCLL) for his pioneering CLL research in 2017. He served as an Editor of Blood from 2007 to 2014. He is a Fellow of the Royal College of Physicians, and the Royal College of Pathologists. He was elected as a member of the American Society for Clinical Investigation and a Fellow of the Academy of Medical Science. He is Chair of the international workshop on non-Hodgkin’s Lymphoma (iwNHL) and Co-Chair of the international workshop for CAR-T cells (iwCART). He serves on the Executive Board and is currently President of the European Hematology Association.
Hospital da Luz, Lisbon, Portugal
Professor Antonio Almeida is currently head of department at Hospital da Luz, Lisbon, Portugal, and also head of the hemato-oncology diagnostic laboratory at the Portuguese Institute of Oncology in Lisbon.
He was awarded his medical degree in 1993 from Cambridge University, UK, and completed his Specialist Training in Hematology in the UK in 2002. Following this, Professor Almeida completed a clinical research fellowship through the Leukaemia Research Fund at Imperial College, London, and was awarded a PhD in 2007 for his work on the molecular characterization and targeted therapy for Inherited GPI Deficiency.
Professor Almeida’s research interests include myeloproliferative and myelodysplastic syndromes, focusing on epigenetic regulation of transcription regulation. He leads a Hematology Epigenetic research group and is the national principal investigator for several clinical trials in CML and MDS.
Professor Almeida has been involved in pre-clinical and clinical teaching since his time as an intern. He is currently Associate Professor at NOVA medical school in Lisbon and has been appointed Founding Dean for the Católica University Medical School. He is heavily involved in post-graduate education: as Chair of the European Hematology Association Curriculum Committee, member of the Education Committee and EHA Secretary in the Association’s Executive Board.
Professor Almeida has written book chapters and is the author of more than 60 articles published in journals including New England Journal of Medicine, Nature Medicine and Blood.
University of Helsinki; Department of Hematology at the Helsinki University Hospital Comprehensive Cancer Center in Finland
Kimmo Porkka, MD, PhD, is a professor of clinical hematology at the University of Helsinki and his current clinical position is Head of the Department of Hematology at the Helsinki University Hospital Comprehensive Cancer Center in Finland.
Professor Porkka received his medical degrees at the Universities of Turku and Helsinki in Finland. He has received clinical training in oncology, internal medicine and hematology.
Professor Porkka`s research experience includes clinical epidemiology, clinical breast cancer research, human molecular genetics (genetic mapping of complex diseases), basic and applied cancer research on characterization of leukemia-specific proteins and ligands (post-doctoral visit at the Burnham Institute, La Jolla, USA).
Professor Porkka`s research relate to molecularly targeted therapies and immunotherapy of hematological malignancies. He has been the principal investigator in several Phase I-III clinical drug studies (academic and company-sponsored) on chronic myeloid leukemia and acute lymphoblastic and myeloid leukemia and performed closely linked translational science projects on leukemic stem cell targeting and immunomodulatory effects of tyrosine kinase inhibitors. Current research of Professor Porkka focuses on individualized therapy of relapsed acute leukemia by high-throughput predictive drug testing ex vivo and molecular profiling aiming in rapid introduction of novel therapies (e.g. by drug repurposing). He is particularly interested in applying mathematical modeling for integration of big disease profiling data sources for clinical translation.
Professor Porkka is the principal investigator in the Finnish Hematology Registry and Biobank (FHRB; fhrb.fi), which is a national, population-based registry and biobanking effort commencing in 2011. He is the past chairman of the Finnish Hematology Association.
Professor Porkka is an active member of the European Hematology Association (EHA), currently serving in the EHA Executive Board and as the chair of the scientific program committee for the EHA annual meeting in 2020.
Professor Porkka has more than 140 original publications in international peer reviewed journals, such as New England Journal of Medicine, Nature, Nature Medicine, Nature Genetics, PNAS, Journal of Clinical Oncology, Blood, and Leukemia.
Institute of Pharmacology and Toxicology, Department of Biomedical Sciences, University of Veterinary Medicine of Vienna, Austria
Professor Veronika Sexl is Chair in the Department of Biomedical Sciences, Veterinary Medical University Vienna, Austria. She completed her doctoral studies at University of Vienna.
Professor Sexl’s research interests include understanding signaling pathways involved in hematopoiesis, leukemogenesis and NK biology, particularly the role of JAK-STAT signaling in cancer and NK cells. Her recent work investigated the role of the cell cycle kinase CDK6 as a transcriptional regulator. Professor Sexl’s laboratory performs translational research using a broad range of techniques such as murine and human cell models, leukemia models, and primary clinical patient material.
Professor Sexl is Incoming Director for the Training Program in Translational Medicine of the American Society for Hematology (ASH) and the European Hematology Association (EHA). Since 2019, Professor Sexl has been Vice-Chair of the International Scientific Committee of the CRIS Cancer Foundation. Professor Sexl is a referee for international journals such as Nature and Blood.
